Astrazeneca Pharma India Share Price Slips to Fresh 52-Week Low at Rs 6,370: Here’s Why
- September 28, 2026
- Posted by: Harsh Piplani
- Category: News
Astrazeneca Pharma India Share Price fell to Rs 6,370, down 2.27% from the previous close of Rs 6,517.85, and marked a fresh 52-week low in a company with a market capitalisation of Rs 16,294.63 crore. The stock opened and also printed its intraday high at Rs 6,490.85 before weakening to the day’s low of Rs 6,370. Turnover stood at Rs 0.11 crore. The supplied data confirms the price event, but it does not establish a company-specific catalyst. For readers tracking Astrazeneca Pharma India Share Price Today, the move is important because it places the stock at the lowest point in its one-year range while leaving the valuation and financial backdrop unchanged in the data set. Univest is tracking the move as a stock news event tied to measurable price action, not a claimed trigger.
Astrazeneca Pharma India Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 6,370 |
| Previous Close | Rs 6,517.85 |
| Today's Move | Rs -147.85 (-2.27%) |
| Open | Rs 6,490.85 |
| High | Rs 6,490.85 |
| Low | Rs 6,370 |
| Turnover | Rs 0.11 crore |
| Market Capitalisation | Rs 16,294.63 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,370. versus the previous close of Rs 6,517.85, a fall of 2.27%. The stock opened at Rs 6,490.85, reached Rs 6,490.85, touched Rs 6,370.
Astrazeneca Pharma India Share Price Today shows a clear gap between the previous close of Rs 6,517.85 and the latest price of Rs 6,370, a decline of Rs 147.85 or 2.27%. The stock opened at Rs 6,490.85, which was also the day’s high, and then slipped to Rs 6,370, matching the fresh 52-week low. That means the session finished at the lowest level seen in the past year, while turnover came to Rs 0.11 crore. With a market capitalisation of Rs 16,294.63 crore, Astrazeneca Pharma India Stock News is now centred on how the share price has moved into a new yearly low zone. The move is factual and event-led; the data confirms the price event, but it does not identify a specific company or market catalyst. For investors reading Astrazeneca Pharma India Share Price Update, the key point is the fresh one-year low itself and the size of the day’s decline relative to the previous close. That sets up the broader fundamental check that follows in Astrazeneca Pharma India Stock Analysis.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 16,294.63 crore |
| P/E Ratio | 96.07x |
| P/B Ratio | 18.02x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.55% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 96.07x, P/B 18.02x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 16294.63 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 96.07x, P/B at 18.02x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.55%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.67x, median ROE of 11.43%, median ROCE of 13.1%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 96.07x |
| Benchmark Median P/E | 32.67x |
| Benchmark Average P/E | 49.35x |
| Benchmark P/E Range | 3.46x to 735.85x |
| Company P/B Ratio | 18.02x |
| Benchmark Median P/B | 2.84x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.43% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 16,294.63 crore |
| Benchmark Median Market Cap | Rs 722.23 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 96.07x, which is above the benchmark median of 32.67x, a difference of +194.06%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.43%, a difference of +101.4%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.1%, a difference of +138.47%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd. | ALIVUS | 16,760.76 | 27.79 | 4.81 | 18.41 | 24.61 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,975.19 | 24.48 | 2.9 | 12.35 | 11.74 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 17,109.18 | 48.59 | 2.4 | 5.97 | 8.69 |
| Marksans Pharma Ltd. | MARKSANS | 15,267.09 | 29.54 | 4.8 | 15.31 | 21.1 |
| Concord Biotech Ltd. | CONCORDBIO | 15,213.29 | 55.25 | 7.34 | 13.54 | 18.04 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 96.07x compared with the displayed peer median of 29.54x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 13.54% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 16,294.63 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India
- Astrazeneca Pharma India Share Price is at Rs 6,370, which is a fresh 52-week low and also the latest day low.
- The stock closed lower by Rs 147.85, or 2.27%, versus the previous close of Rs 6,517.85.
- Market capitalisation stands at Rs 16,294.63 crore, giving Astrazeneca Pharma India Share Price a large numeric base in the data set.
- P/E is 96.07 and P/B is 18.02, both above the Healthcare benchmark median shown in the sector snapshot.
- ROE is 23.02% and ROCE is 31.24%, and both are above the sector median and average in the supplied comparison.
About Astrazeneca Pharma India
Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company through its listed equity profile and financial disclosures, including quarterly revenue and net profit figures, along with return ratios, book value and dividend yield. In this article, Univest is focusing on Astrazeneca Pharma India Share Price through a market-data lens that combines the price event, valuation profile and sector comparison. The company name, sector and industry are the verified reference points available here, and the rest of the analysis is built only from the supplied financial and benchmark figures. For readers following Astrazeneca Pharma India Stock News, the company context remains tied to these disclosed numbers.
Track Astrazeneca Pharma India Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Track Astrazeneca Pharma India Share Price on Univest to follow live share price updates, market cap, fundamental ratios, shareholding pattern when available, 52-week levels and company-level market insights in one place. Univest also brings together Astrazeneca Pharma India Share Price Today, valuation metrics and stock news so readers can revisit the same data as the market updates.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Astrazeneca Pharma India Share Price fall today?
Ans. Astrazeneca Pharma India Share Price fell 2.27% to Rs 6,370 and marked a fresh 52-week low. The supplied data confirms the price event, but it does not establish a company-specific catalyst for the move.
What is the Astrazeneca Pharma India Share Price today?
Ans. Astrazeneca Pharma India Share Price today is Rs 6,370. It is lower than the previous close of Rs 6,517.85 and sits at the latest day low in the current session.
Is Astrazeneca Pharma India at a 52-week low?
Ans. Yes. Astrazeneca Pharma India Share Price touched Rs 6,370, which is the fresh 52-week low in the supplied data. That makes it a one-year low event rather than an all-time low statement.
What is the market capitalisation of Astrazeneca Pharma India?
Ans. Astrazeneca Pharma India has a market capitalisation of Rs 16,294.63 crore. That figure places the stock in a company with a sizable listed equity base in the Healthcare sector. The company operates in the Healthcare sector.
How does Astrazeneca Pharma India look on valuation?
Ans. Astrazeneca Pharma India Share Price is linked to a P/E ratio of 96.07 and a P/B ratio of 18.02. Both are above the healthcare benchmark median shown in the sector snapshot.
What do ROE and ROCE show for Astrazeneca Pharma India?
Ans. ROE is 23.02% and ROCE is 31.24% for Astrazeneca Pharma India. Both ratios are above the sector median and average in the supplied healthcare benchmark. ROE stands at 23.02%. ROCE stands at 31.24%.
How does Astrazeneca Pharma India compare with peers?
Ans. Astrazeneca Pharma India Share Price is associated with a higher P/E than Glenmark Life Sciences, Alembic Pharmaceuticals, Jubilant Pharmova, Marksans Pharma and Concord Biotech in the supplied peer list. Comparable listed companies include Glenmark Life Sciences Ltd., Alembic Pharmaceuticals Ltd..
What does the latest quarterly financial data show?
Ans. Revenue was Rs 6,827.9 crore in Jun 26 and net profit was Rs 379.3 crore. The same company reported revenue of Rs 5,263.1 crore and net profit of Rs 558.3 crore in Jun 25.
Where can investors track Astrazeneca Pharma India Share Price?
Ans. Investors can track Astrazeneca Pharma India Share Price on Univest for live price updates, valuation ratios, market cap, 52-week levels and stock news in one place. The stock moved -2.27% during the session.
